Expression of Concern: WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: A phase 2, randomized, double blind, placebo controlled study

Expression of Concern: WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: A phase 2, randomized, double blind, placebo controlled study

Following the publication of this article [1], concerns were raised about the study's compliance with a Tunisian decree (n° 90-1401, chapter I Article 2) on the use of minors in clinical research. T… [+1766 chars]
Expression of Concern: WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: A phase 2, randomized, double blind, placebo controlled study - FHMnews